São Paulo, Brazil: Subjects who ingest oral formulations containing 300mg of CBD do not test positive later for the presence of THC in their blood plasma, according to data published in the journal Cannabis and Cannabinoid Research.
A team of Brazilian researchers assessed whether CBD interconverts to either delta-8 or delta-9 THC following human ingestion in a group of 120 participants. Authors reported no evidence of any bioconversion of CBD in test subjects, regardless of whether they ingested CBD on either full or empty stomachs.
They concluded: “The findings presented here are consonant with previous evidence suggesting that the oral administration of CBD in a corn oil formulation is a safe route for the administration of the active substance without bioconversion to THC in humans under different conditions (fasting and normal feeding). The results also add to the knowledge built over 40 years of research that CBD-based therapies are safe and well tolerated in humans.”
The study’s findings should negate concerns that the use of purified forms of CBD could potentially lead to a positive drug test result for cannabis. Although such incidents have been reported anecdotally, they are most likely due to the fact that many CBD products also contain detectable levels of THC.
Full text of the study, “Oral cannabidiol does not convert to delta-8-THC or delta-9-THC in humans: A Pharmacokinetic study in healthy subjects,” appears in Cannabis and Cannabinoid Research. Additional information is available in the NORML fact sheet, ”FAQs About Cannabidiol (CBD).”